Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 90, Issue 2-3, 2014, Pages 27-37

  Schuchardt, Jan Philipp ^a   Schmidt, Simone ^a   Kressel, Gaby ^a   Willenberg, Ina ^c   Hammock, Bruce D ^b   Hahn, Andreas ^a   Schebb, Nils Helge ^c  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Arachidonic acid; DHA; Diols; Eicosanoids; EPA; Epoxides; Hyperlipidemia; Omega 3 fatty acids; PUFA

Indexed keywords

ARACHIDONIC ACID; DHA; DIOLS; EICOSANOIDS; EPA; EPOXIDES; HYPERLIPIDEMIA; OMEGA-3 FATTY ACIDS; PUFA;

ADULT; DIETARY SUPPLEMENTS; EICOSAPENTAENOIC ACID; ERYTHROCYTE MEMBRANE; FATTY ACIDS; FATTY ACIDS, OMEGA-3; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MIDDLE AGED; OXYLIPINS; YOUNG ADULT;

EID: 84895907696     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.12.008     Document Type: Article

References (35)

1. Jump D.B., Depner C.M., Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J. Lipid Res. 2012, 53:2525-2545.
2. Arnold C., Konkel A., Fischer R., Schunck W.-H. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol. Rep. 2010, 62:536-547.
3. Buczynski M.W., Dumlao D.S., Dennis E.A. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 2009, 50:1015-1038.
4. Bylund J., Kunz T., Valmsen K., Oliw E.H. Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J. Pharmacol. Exp. Ther. 1998, 284:51-60.
5. Kroetz D.L., Zeldin D.C. Cytochrome P450 pathways of arachidonic acid metabolism. Curr. Opin. Lipidol. 2002, 13:273-283.
6. Morisseau C., Inceoglu B., Schmelzer K., Tsai H.-J., Jinks S.L., Hegedus C.M., Hammock B.D. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J. Lipid Res. 2010, 51:3481-3490.
7. Morisseau C., Hammock B.D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 2005, 45:311-333.
8. Morisseau C., Hammock B.D. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu. Rev. Pharmacol. Toxicol. 2013, 53:37-58.
9. Mozaffarian D., Wu J.H.Y. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011, 58:2047-2067.
10. Vidgren H.M., Agren J.J., Schwab U., Rissanen T., Hänninen O., Uusitupa M.I. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 1997, 32:697-705.
11. Cao J., Schwichtenberg K.A., Hanson N.Q., Tsai M.Y. Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin. Chem. 2006, 52:2265-2272.
12. Neubronner J., Schuchardt J.P., Kressel G., Merkel M., von Schacky C., Hahn A. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur. J. Clin. Nutr. 2011, 65:247-254.
13. Harris W.S., von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev. Med. 2004, 39:212-220.
14. Schmitz G., Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 2008, 47:147-155.
15. Arnold C., Markovic M., Blossey K., Wallukat G., Fischer R., Dechend R., Konkel A., von Schacky C., Luft F.C., Muller D.N., Rothe M., Schunck W.-H. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J. Biol. Chem. 2010, 285:32720-32733.
16. Westphal C., Konkel A., Schunck W.-H. CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?. Prostaglandins Other Lipid Mediat. 2011, 96:99-108.
17. Brash A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 1999, 274:23679-23682.
18. Fer M., Dréano Y., Lucas D., Corcos L., Salaün J.-P., Berthou F., Amet Y. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch. Biochem. Biophys. 2008, 471:116-125.
19. B. Inceoglu, K.M. Wagner, J. Yang, A. Bettaieb, N.H. Schebb, S.H. Hwang, C. Morisseau, F.G. Haj, B.D. Hammock, Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes, Proceedings of the National Academy of Science USA 109, 2012, 11390-11395.
20. G. Zhang, D. Panigrahy, L.M. Mahakian, J. Yang, J.-Y. Liu, K.S. Stephen Lee, H.I. Wettersten, A. Ulu, X. Hu, S. Tam, S.H. Hwang, E.S. Ingham, M.W. Kieran, R.H. Weiss, K.W. Ferrara, B.D. Hammock, Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis, Proceedings of the National Academy of Sciences USA 110, 2013, 6530-6535.
21. Shearer G.C., Harris W.S., Pedersen T.L., Newman J.W. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 2010, 51:2074-2081.
22. Gomolka B., Siegert E., Blossey K., Schunck W.-H., Rothe M., Weylandt K.H. Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. Prostaglandins Other Lipid Mediat. 2011, 94:81-87.
23. Psychogios N., Hau D.D., Peng J., Guo A.C., Mandal R., Bouatra S., Sinelnikov I., Krishnamurthy R., Eisner R., Gautam B., Young N., Xia J., Knox C., Dong E., Huang P., Hollander Z., Pedersen T.L., Smith S.R., Bamforth F., Greiner R., McManus B., Newman J.W., Goodfriend T., Wishart D.S. The human serum metabolome. PLoS ONE 2011, 6:e16957.
24. Keenan A.H., Pedersen T.L., Fillaus K., Larson M.K., Shearer G.C., Newman J.W. Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J. Lipid Res. 2012, 53:1662-1669.
25. Strassburg K., Huijbrechts A.M.L., Kortekaas K.A., Lindeman J.H., Pedersen T.L., Dane A., Berger R., Brenkman A., Hankemeier T., van Duynhoven J., Kalkhoven E., Newman J.W., Vreeken R.J. Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: application in cardiac surgery. Anal. Bioanal. Chem. 2012, 404:1413-1426.
26. Schuchardt J.P., Schmidt S., Kressel G., Dong H., Willenberg I., Hammock B.D., Hahn A., Schebb N.H. Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men. Prostaglandins Leukot. Essent. Fatty Acids 2013, 89:19-29.
27. Yang J., Schmelzer K., Georgi K., Hammock B.D. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal. Chem. 2009, 81:8085-8093.
28. Schebb N.H., Inceoglu B., Ahn K.C., Morisseau C., Gee S.J., Hammock B.D. Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects. Environ. Sci. Technol. 2011, 45:3109-3115.
29. Burdge G.C., Calder P.C. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod. Nutr. Dev. 2005, 45:581-597.
30. Brenna J.T., Salem N., Sinclair A.J., Cunnane S.C. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot. Essent. Fatty Acids 2009, 80:85-91.
31. Plourde M., Cunnane S.C. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl. Physiol. Nutr. Metab. 2007, 32:619-634.
32. K.R. Schmelzer, L. Kubala, J.W. Newman, I.-H. Kim, J.P. Eiserich, B.D. Hammock, Soluble epoxide hydrolase is a therapeutic target for acute inflammation, Proceedings of the National Academy of Science USA. 102, 2005 9772-9777.
33. Agbor L.N., Walsh M.T., Boberg J.R., Walker M.K. Elevated blood pressure in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids. Toxicol. Appl. Pharmacol. 2012, 264:351-360.
34. Jung F., Schulz C., Blaschke F., Muller D.N., Mrowietz C., Franke R.P., Lendlein A., Schunck W.-H. Effect of cytochrome P450-dependent epoxyeicosanoids on Ristocetin-induced thrombocyte aggregation. Clin. Hemorheol. Microcirc. 2012, 52:403-416.
35. Weylandt K.H., Chiu C.Y., Gomolka B., Waechter S.F., Wiedenmann.B. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat. 2012, 97:73-82.